Once Again, Hype Overshadows Data in Breast Cancer Screening Debate

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Studies assessing the merits of cancer screening tend to get a lot of play in the news media. It seems every six months or so a new study makes a big splash.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.
Otis W. Brawley, MD, MACP
Chief scientific and medical officer, American Cancer Society

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login